CRP and myocardial infarction: In the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial, patients with prior myocardial infarction and elevated high-sensitivity C-reactive protein (hs-CRP) levels, treated with 150 mg canakinumab, a human anti-IL-1β monoclonal antibody, every 3 months during followup, showed a 15% relative risk reduction in the primary composite endpoint of death, nonfatal stroke, and nonfatal myocardial infarction compared to patients receiving standard treatment [68].